






This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
This provider hasn't verified their profile's information. Are you the owner of this center? Claim your listing to better manage your presence on Recovery.com.
This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
You pay directly for treatment out of pocket. This approach can offer enhanced privacy and flexibility, without involving insurance. Exact costs vary based on program and length of stay. Contact the center for specific details.
Ona Treatment Center, located in Browns Valley, California, is a detox and residential treatment center offering a 28-day program for adults with primary substance use disorders and co-occurring mental health disorders. Their mission is to help guide clients towards a brighter, healthier future and provide them with the care they need to overcome addiction. Ona Treatment Center offers a comprehensive approach to treatment, incorporating individualized treatment plans, holistic care, evidence-based therapies, and life skills development. Clients may participate in therapies like acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT), art therapy, meditation and mindfulness, and motivational interviewing. Ona Treatment Center is accredited by the Joint Commission and accepts insurance.
This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
The Joint Commission accreditation is a voluntary, objective process that evaluates and accredits healthcare organizations (like treatment centers) based on performance standards designed to improve quality and safety for patients. To be accredited means the treatment center has been found to meet the Commission's standards for quality and safety in patient care.
Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT

Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.

Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.

Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.